Description

Tirzepatide Research Grade Compound Handbook Product Overview

As the first GIP/GLP-1 dual receptor agonist, Tirzepatide can significantly reduce glycosylated hemoglobin (HbA1c reaches 2.4%) in type 2 diabetes patients and achieve an average weight loss of 22.5% in obese patients by co regulating insulin secretion and energy metabolism

main features
·   High purity: HPLC verification purity ≥ 99%
·   Research focus: regulate insulin secretion and energy metabolism, and significantly reduce glycosylated hemoglobin in type 2 diabetes patients
·   Appearance: Peptide in freeze-dried (powder) form
·   Packaging specification: 10mg standard packaging (can be customized according to requirements)
·   Cold chain transportation: Ensure temperature throughout the entire process (-20 ℃)

Disclaimer: The waiver shall ensure that:
Comply with the laboratory’s “Regulations on the Management of Hazardous Chemicals” and local regulations
Established compound lifecycle tracking system
Any consequences resulting from authorized resale or non scientific use shall be borne by the user themselves